Revolution Beauty Group Valuation
Is REVB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of REVB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: REVB (£0.12) is trading below our estimate of fair value (£0.5)
Significantly Below Fair Value: REVB is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for REVB?
Key metric: As REVB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is REVB's PS Ratio? | |
|---|---|
| PS Ratio | 0.2x |
| Sales | UK£173.31m |
| Market Cap | UK£39.27m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | -17.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does REVB's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.3x | ||
SIS Science in Sport | 1.1x | 8.9% | UK£59.9m |
VLG Venture Life Group | 1x | 9.6% | UK£49.6m |
CRL Creightons | 0.4x | n/a | UK£23.3m |
PXS Provexis | 14.8x | n/a | UK£11.8m |
REVB Revolution Beauty Group | 0.2x | 2.6% | UK£39.3m |
Price-To-Sales vs Peers: REVB is good value based on its Price-To-Sales Ratio (0.2x) compared to the peer average (4.3x).
Price to Sales Ratio vs Industry
How does REVB's PS Ratio compare vs other companies in the European Personal Products Industry?
Price-To-Sales vs Industry: REVB is good value based on its Price-To-Sales Ratio (0.2x) compared to the European Personal Products industry average (1.4x).
Price to Sales Ratio vs Fair Ratio
What is REVB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.2x |
| Fair PS Ratio | 0.5x |
Price-To-Sales vs Fair Ratio: REVB is good value based on its Price-To-Sales Ratio (0.2x) compared to the estimated Fair Price-To-Sales Ratio (0.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | UK£0.12 | UK£0.63 +408.1% | 20.0% | UK£0.75 | UK£0.50 | n/a | 2 |
| Nov ’25 | UK£0.15 | UK£0.63 +322.3% | 20.0% | UK£0.75 | UK£0.50 | n/a | 2 |
| Oct ’25 | UK£0.17 | UK£0.63 +257.1% | 20.0% | UK£0.75 | UK£0.50 | n/a | 2 |
| Sep ’25 | UK£0.21 | UK£0.63 +192.1% | 20.0% | UK£0.75 | UK£0.50 | n/a | 2 |
| Aug ’25 | UK£0.20 | UK£0.63 +213.3% | 20.0% | UK£0.75 | UK£0.50 | n/a | 2 |
| Jul ’25 | UK£0.24 | UK£0.63 +161.5% | 20.0% | UK£0.75 | UK£0.50 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Ontex Group
€620.0m
Develops, produces, and supplies personal hygiene products and solutions for baby, feminine, and adult care in Belgium, the United Kingdom, the United States, Italy, France, and internationally.
0QVQ
€7.59
7D
2.4%
1Y
7.7%
McBride
UK£182.8m
Manufactures and sells private label household and personal care products to retailers and brand owners in the United Kingdom, Germany, France, Italy, Spain, rest of Europe, Asia-Pacific, and internationally.It operates through five segments: Liquids, Powders, Unit dosing, Aerosols, and Asia Pacific.
MCBL
UK£1.05
7D
0.5%
1Y
71.3%
Accrol Group Holdings
UK£123.7m
Engages in the soft tissue paper converting business in the United Kingdom and Europe.
ACRL
UK£0.39
7D
0%
1Y
9.6%